# SWOG S2001 (NCT04548752)

> Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04548752
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8
- Interventions: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib; Pembrolizumab
- Enrollment: 68
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on SWOG S2001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=swog-s2001-nct04548752